Roberto Pedone to-day just before market close:
"From a technical perspective, GERN is exploding higher here right off its 50-day moving average of $1.50 with lighter-than-average volume. This move is also starting to push shares of GERN back above its 200-day moving average of $1.59. Shares of GERN are now quickly moving within range of triggering a major breakout trade. That trade will hit if GERN manages to clear some key overhead resistance levels at $1.78 to $1.83 with high volume.
Traders should now look for long-biased trades in GERN as long as it’s trending above some key near-term support at $1.47, and then once it sustains a move or close above those breakout levels with volume that hits near or above 1.17 million shares. If that breakout triggers soon, then GERN will set up to re-fill some of its massive gap down zone from last September that started near $3."
Any comments? Just serious ones only, please!
Black, this board is being infested heavily by "those" who have no deeper understanding of technical analyses although claim to be so. In any case, I was seeking some insightful comments on the article by Pedone which, in my opinion, seems to match prediction if you plug in anticipated Imetelstat trials results and date as well as my expectations for news coming out from the company. The silence maintained by the management is kind of mysterious; but, something seems to be cooking.
Regarding EXEL, the analysts are still neutral; however, the latest (to-day's) recommendation by ThompsonReuters, has improved to a "buy". Their analysis, generally, in my view, is not appropriate. For Exelixis, Credit Sussie does a much more thorough and appropriate job, based on which, Exelixis is likley to be still range-bound. However, it appears to me that the company is pushing very hard for wider application of Cabo in which it should most likely succeed. The coolness expressed by investors, especially institutional ones, is perhaps "Wait &Ssee" based. But, your money is apparently safe in this stock with a decent chance of appreciation once expectation for Cabo materializes and company's collaboration with several major pharmas get going well. I do not think the company is going to look for more financing; but, traditional analysts do their deduction based on earnings trend and finances (although the company has $600M+ cash in hand), which the company can't have better due to commercialization costs for MTC application of Cabo and costs for other 30 on-going and advancing trials and, therefore, the "wait & See" attitude. Most of these trials, however, receive fundng from collaborators.
It is clear to me that you did not grasp the monkey action I have been referring to and my idea of posting this quote!! This has nothing to do with that! The monkey action I referred to was for the current situation and not in this prediction for the future! You should be able to separate the two situations.
This one I posted asking for comments because the author Pedone's scenario jives very well with anticipated development of fundamental factors for the company. This rarely is the case for purely technical analyses and the author seems to have combined the two. I guess that's too much for you to understand!!
Also, absence of sensible response to my original post means that the smarter people looking at the posts on this board are disappearing!!
Sentiment: Strong Buy